Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sirolimus

FDA-approved product (solution, oral), marketed as Fyarro, Hyftor, Rapamune and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Sirolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenoma sebaceum
  • Angiofibroma
  • Cancer
  • Delayed Graft Function
  • Eye disease
  • Kidney transplant
  • Neoplasm
  • Tuberous sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors; Other ophthalmologicals
FDA pharmacologic class
Kinase Inhibitor; mTOR Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sirolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sirolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

    NCT01088048 · start 2010-03-25

    Registered record
    Registry ID
    NCT01088048
    Conditions
    Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
    Interventions
    Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03-25
    Completion
    2015-04-28
    Enrolment
    241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIndolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
    InterventionIdelalisib; Rituximab; Bendamustine; Ofatumumab +5 more
    PhasePhase 1
    Registry statusCompleted

  • Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

    NCT00976248 · start 2009-11

    Registered record
    Registry ID
    NCT00976248
    Conditions
    Waldenstrom's Macroglobulinemia
    Interventions
    RAD001
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-11
    Completion
    2018-07
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenstrom's Macroglobulinemia
    InterventionRAD001
    PhasePhase 2
    Registry statusCompleted

  • Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

    NCT01007942 · start 2009-10

    Registered record
    Registry ID
    NCT01007942
    Conditions
    HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
    Interventions
    everolimus; Placebo; vinorelbine; trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10
    Completion
    2015-06
    Enrolment
    569

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
    Interventioneverolimus; Placebo; vinorelbine; trastuzumab
    PhasePhase 3
    Registry statusCompleted

  • Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma

    NCT00942747 · start 2009-07

    Registered record
    Registry ID
    NCT00942747
    Conditions
    Recurrent or Refractory Primary CNS Lymphoma
    Interventions
    temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-07
    Completion
    2014-06
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent or Refractory Primary CNS Lymphoma
    Interventiontemsirolimus
    PhasePhase 2
    Registry statusUnknown

  • Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer

    NCT01313390 · start 2009-06

    Registered record
    Registry ID
    NCT01313390
    Conditions
    Head and Neck Cancer
    Interventions
    docetaxel; everolimus; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2009-06
    Completion
    2011-04
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    Interventiondocetaxel; everolimus; laboratory biomarker analysis; pharmacological study
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Polycystic Liver Disease in Kidney Transplant

    NCT00934791 · start 2009-02

    Registered record
    Registry ID
    NCT00934791
    Conditions
    Polycystic Liver Disease
    Interventions
    Tacrolimus; Sirolimus; Mycophenolate Mofetil; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2009-02
    Completion
    2012-12
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Liver Disease
    InterventionTacrolimus; Sirolimus; Mycophenolate Mofetil; Prednisone
    PhaseNot applicable
    Registry statusTerminated

  • Doxil, Bevacizumab and Temsirolimus Trial

    NCT00761644 · start 2008-08-21

    Registered record
    Registry ID
    NCT00761644
    Conditions
    Advanced Cancer
    Interventions
    Doxil; Bevacizumab; Temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08-21
    Completion
    2019-03-28
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer
    InterventionDoxil; Bevacizumab; Temsirolimus
    PhasePhase 1
    Registry statusCompleted

  • Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

    NCT00855114 · start 2008-07

    Registered record
    Registry ID
    NCT00855114
    Conditions
    Breast Cancer
    Interventions
    everolimus; therapeutic conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2008-07
    Completion
    2009-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventioneverolimus; therapeutic conventional surgery
    PhasePhase 2
    Registry statusWithdrawn

  • RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

    NCT00729638 · start 2008-06

    Registered record
    Registry ID
    NCT00729638
    Conditions
    Multiple Myeloma
    Interventions
    RAD001; lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    2009-11
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionRAD001; lenalidomide
    PhasePhase 1
    Registry statusCompleted

  • Optical Coherence Tomography in Long Lesions

    NCT01133925 · start 2008-05

    Registered record
    Registry ID
    NCT01133925
    Conditions
    Coronary Artery Disease
    Interventions
    Resolute Sprint; Sirolimus Eluting Stent; Paclitaxel Eluting Stent; Zotarolimus eluting stent
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-05
    Completion
    2011-05
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionResolute Sprint; Sirolimus Eluting Stent; Paclitaxel Eluting Stent; Zotarolimus eluting stent
    PhasePhase 4
    Registry statusUnknown

  • Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

    NCT00634920 · start 2008-03

    Registered record
    Registry ID
    NCT00634920
    Conditions
    Renal Function
    Interventions
    everolimus; cyclosporine A; Enteric Coated Mycophenolate Sodium (EC-MPS); corticosteroids; Basiliximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-03
    Completion
    2013-05
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Function
    Interventioneverolimus; cyclosporine A; Enteric Coated Mycophenolate Sodium (EC-MPS); corticosteroids +1 more
    PhasePhase 4
    Registry statusCompleted

  • Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients

    NCT00457119 · start 2007-02

    Registered record
    Registry ID
    NCT00457119
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    RAD001
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-02
    Completion
    2009-11
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionRAD001
    PhasePhase 1
    Registry statusCompleted

  • S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

    NCT00352443 · start 2006-09

    Registered record
    Registry ID
    NCT00352443
    Conditions
    Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    everolimus; lapatinib ditosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-09
    Completion
    2013-09
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Unspecified Adult Solid Tumor, Protocol Specific
    Interventioneverolimus; lapatinib ditosylate
    PhasePhase 1
    Registry statusCompleted

  • Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

    NCT00335764 · start 2006-04

    Registered record
    Registry ID
    NCT00335764
    Conditions
    Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventions
    sorafenib tosylate; erlotinib hydrochloride; tipifarnib; temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2012-09
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventionsorafenib tosylate; erlotinib hydrochloride; tipifarnib; temsirolimus
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

    NCT00133367 · start 2005-08

    Registered record
    Registry ID
    NCT00133367
    Conditions
    Multiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Myelogenous Leukemia; Lymphoblastic Leukemia
    Interventions
    Tacrolimus; Sirolimus; G-CSF; Antithymocyte globulin; Thymoglobulin; Fludarabine; Melphalan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-08
    Completion
    2011-11
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Myelogenous Leukemia +1 more
    InterventionTacrolimus; Sirolimus; G-CSF; Antithymocyte globulin +3 more
    PhasePhase 2
    Registry statusCompleted